Lenzilumab
Lenzilumab
Lenzilumab (pronounced len-zil-yoo-mab) is a monoclonal antibody designed for the treatment of various diseases. It is currently being studied for its potential use in the treatment of COVID-19 and other conditions.
Etymology
The name "Lenzilumab" is derived from the combination of the prefix "Lenzi-", which is a proprietary designation by the drug's developer, Humanigen, and "-lumab", a suffix used in the International Nonproprietary Names (INN) for monoclonal antibodies.
Usage
Lenzilumab is currently being investigated for its potential use in treating patients with COVID-19. It is designed to target and neutralize granulocyte-macrophage colony-stimulating factor (GM-CSF), a critical cytokine that drives the hyperinflammatory immune response associated with COVID-19.
Related Terms
- Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- COVID-19: An infectious disease caused by a newly discovered coronavirus.
- Cytokine: A type of protein that plays an important role in cell signaling.
- GM-CSF: A protein secreted by certain immune cells that stimulates the production of other immune cells.
See Also
External links
- Medical encyclopedia article on Lenzilumab
- Wikipedia's article - Lenzilumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski